1NZM
 
 | | NMR structure of the parallel-stranded DNA quadruplex d(TTAGGGT)4 complexed with the telomerase inhibitor RHPS4 | | Descriptor: | 3,11-DIFLUORO-6,8,13-TRIMETHYL-8H-QUINO[4,3,2-KL]ACRIDIN-13-IUM, 5'-D(*TP*TP*AP*GP*GP*GP*T)-3', POTASSIUM ION | | Authors: | Gavathiotis, E, Heald, R.A, Stevens, M.F.G, Searle, M.S. | | Deposit date: | 2003-02-18 | | Release date: | 2003-11-04 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | Drug Recognition and Stabilisation of the Parallel-stranded DNA Quadruplex d(TTAGGGT)4 Containing the Human Telomeric Repeat
J.Mol.Biol., 334, 2003
|
|
2K7W
 | | BAX Activation is Initiated at a Novel Interaction Site | | Descriptor: | Apoptosis regulator BAX, Bcl-2-like protein 11 | | Authors: | Gavathiotis, E, Suzuki, M, Davis, M.L, Pitter, K, Bird, G.H, Katz, S.G, Tu, H.C, Kim, H, Cheng, E.H, Tjandra, N, Walensky, L.D. | | Deposit date: | 2008-08-27 | | Release date: | 2008-10-21 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | BAX activation is initiated at a novel interaction site.
Nature, 455, 2008
|
|
1QSX
 | | SOLUTION NMR STRUCTURE OF THE 2:1 HOECHST 33258-D(CTTTTGCAAAAG)2 COMPLEX | | Descriptor: | 2'-(4-HYDROXYPHENYL)-5-(4-METHYL-1-PIPERAZINYL)-2,5'-BI-BENZIMIDAZOLE, 5'-D(CP*TP*TP*TP*TP*GP*CP*AP*AP*AP*AP*G)-3', SODIUM ION | | Authors: | Gavathiotis, E, Sharman, G.J, Searle, M.S. | | Deposit date: | 1999-06-24 | | Release date: | 2000-02-07 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | Sequence-dependent variation in DNA minor groove width dictates orientational preference of Hoechst 33258 in A-tract recognition: solution NMR structure of the 2:1 complex with d(CTTTTGCAAAAG)(2).
Nucleic Acids Res., 28, 2000
|
|
1NP9
 | |
5ITA
 | | Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM | | Descriptor: | N-{2-cyano-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}propane-1-sulfonamide, Serine/threonine-protein kinase B-raf | | Authors: | Wu, Y, Gavathiotis, E. | | Deposit date: | 2016-03-16 | | Release date: | 2016-08-10 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (1.95 Å) | | Cite: | An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling
Cancer Cell, 30, 2016
|
|
6P3D
 | | The co-crystal structure of BRAF(V600E) with ponatinib | | Descriptor: | 1,2-ETHANEDIOL, 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide, AMMONIUM ION, ... | | Authors: | Agianian, B, Gavathiotis, E. | | Deposit date: | 2019-05-23 | | Release date: | 2020-09-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.11 Å) | | Cite: | Inhibitors of BRAF dimers using an allosteric site.
Nat Commun, 11, 2020
|
|
6P7G
 | | The co-crystal structure of BRAF(V600E) with PHI1 | | Descriptor: | 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, 3-[(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-({[2-(morpholin-4-yl)ethyl]amino}methyl)-3-(trifluoromethyl)phenyl]benzamide, Serine/threonine-protein kinase B-raf | | Authors: | Agianian, B, Gavathiotis, E. | | Deposit date: | 2019-06-05 | | Release date: | 2020-09-23 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Inhibitors of BRAF dimers using an allosteric site.
Nat Commun, 11, 2020
|
|
2GF5
 | | Structure of intact FADD (MORT1) | | Descriptor: | FADD protein | | Authors: | Carrington, P.E, Sandu, C, Wei, Y, Hill, J.M, Morisawa, G, Huang, T, Gavathiotis, E, Wei, Y, Werner, M.H. | | Deposit date: | 2006-03-21 | | Release date: | 2006-06-27 | | Last modified: | 2024-05-29 | | Method: | SOLUTION NMR | | Cite: | The Structure of FADD and Its Mode of Interaction with Procaspase-8
Mol.Cell, 22, 2006
|
|
4S0P
 | |
4S0O
 | |
4RZV
 | | Crystal structure of the BRAF (R509H) kinase domain monomer bound to Vemurafenib | | Descriptor: | N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide, Serine/threonine-protein kinase B-raf | | Authors: | Wu, Y, Gavathiotis, E. | | Deposit date: | 2014-12-24 | | Release date: | 2016-08-10 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.994 Å) | | Cite: | An integrated model of RAF inhibitor action predicts
inhibitor activity against oncogenic BRAF signaling
Cancer Cell, 30, 2016
|
|
4RZW
 | | Crystal structure of BRAF (R509H) kinase domain bound to AZ628 | | Descriptor: | 3-(2-cyanopropan-2-yl)-N-{4-methyl-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}benzamide, Serine/threonine-protein kinase B-raf | | Authors: | Wu, Y, Gavathiotis, E. | | Deposit date: | 2014-12-24 | | Release date: | 2016-08-10 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (3.493 Å) | | Cite: | An integrated model of RAF inhibitor action predicts
inhibitor activity against oncogenic BRAF signaling
Cancer Cell, 30, 2016
|
|
